F-18-fluorothymidine-PET evaluation of bone marrow transplant in a rat model

Nuclear Medicine Communications

Volumn 31, Issue 2, 2010, Pages 152-158

  Awasthi, Vibhudutta ^a   Holter, Jennifer ^a   Thorp, Kristin ^a   Anderson, Stacy ^a   Epstein, Robert ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Bone marrow transplant; F 18 fluorothymidine; Positron emission tomography

Indexed keywords

3' FLUOROTHYMIDINE F 18; TRACER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BONE MARROW TRANSPLANTATION; CATHETER ABLATION; CONVALESCENCE; FEMALE; HISTOLOGY; HUMERUS; HYPOTHESIS; INFORMATION; INJURY; NON INVASIVE PROCEDURE; NONHUMAN; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE STUDY; RADIATION DOSE; RAT; STERNUM; WHOLE BODY RADIATION; WISTAR FURTH RAT;

ANIMALS; BONE MARROW; BONE MARROW TRANSPLANTATION; DIDEOXYNUCLEOSIDES; MODELS, ANIMAL; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, INBRED WF;

EID: 75149171912     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283339f92     Document Type: Article

References (29)

1. Ballon D, Watts R, Dyke JP, Lis E, Morris MJ, Scher HI, et al. Imaging therapeutic response in human bone marrow using rapid whole-body MRI. Magn Reson Med 2004; 52:1234-1238.
2. Blebea JS, Houseni M, Torigian DA, Fan C, Mavi A, Zhuge Y, et al. Structural and functional imaging of normal bone marrow and evaluation of its age-related changes. Semin Nucl Med 2007; 37:185-194.
3. Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Effect of colonystimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 2005; 32:1406-1411.
4. Teo BK, Badiee S, Hadi M, Lam T, Johnson L, Seo Y, et al. Correcting tumour SUV for enhanced bone marrow uptake: retrospective 18F-FDG PET/CT studies. Nucl Med Commun 2008; 29:359-366.
5. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003; 44:2027-2032.
6. Agool A, Schot BW, Jager PL, Vellenga E. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med 2006; 47:1592-1598.
7. Been LB, Elsinga PH, De Vries J, Cobben DC, Jager PL, Hoekstra HJ, et al. Positron emission tomography in patients with breast cancer using (18)F-30-deoxy-30-fluoro-l-thymidine ((18)F-FLT)-a pilot study. Eur J Surg Oncol 2006; 32:39-43.
8. Francis DL, Visvikis D, Costa DC, Arulampalam TH, Townsend C, Luthra SK, et al. Potential impact of [18F]30-deoxy-30-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003; 30:988-994.
9. Grierson JR, Shields AF. Radiosynthesis of 30-deoxy-30-[(18)F] fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000; 27:143-156.
10. Halter G, Buck AK, Schirrmeister H,Wurziger I, Liewald F, Glatting G, et al. [18F]3-deoxy-30-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? J Thorac Cardiovasc Surg 2004; 127:1093-1099.
11. Van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, De Vries EF, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004; 45:695-700.
12. Visvikis D, Francis D, Mulligan R, Costa DC, Croasdale I, Luthra SK, et al. Comparison of methodologies for the in vivo assessment of 18FLT utilization in colorectal cancer. Eur J Nucl Med Mol Imaging 2004; 31:169-178.
13. Carr ML, Lerner MR, Hanas JS, Pennington LR, Brackett DJ, Epstein RB. A rat model of syngeneic bone marrow transplantation during breast cancer therapy. Bone Marrow Transplant 2003; 31:1037-1041.
14. Holter J, Saste V, Anderson SL, Do S, Lerner M, Brackett DJ, et al. Immunological aspects of tumor growth in a rat model following hematopoietic transplantation. J of Inves Med 2005; 53:S304-S305.
15. Yee GC, McGuire TR. Allogeneic bone marrow transplantation in the treatment of hematologic diseases. Clin Pharm 1985; 4:149-160.
16. Sale GE, Buckner CD. Pathology of bone marrow in transplant recipients. Hematol Oncol Clin North Am 1988; 2:735-756.
17. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005; 43:153-167.
18. Wells P, West C, Jones T, Harris A, Price P. Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. Biochim Biophys Acta 2004; 1705:91-102.
19. Christman D, Crawford EJ, Friedkin M,Wolf AP. Detection of DNA synthesis in intact organisms with positron-emitting (methyl-11C)thymidine. Proc Natl Acad Sci U S A 1972; 69:988-992.
20. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med 2008; 49 (Suppl 2):64S-80S.
21. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4:1334-1336.
22. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol 1996; 23:17-22.
23. Toyohara J, Hayashi A, Sato M, Gogami A, Tanaka H, Haraguchi K, et al. Development of radioiodinated nucleoside analogs for imaging tissue proliferation: comparisons of six 5-iodonucleosides. Nucl Med Biol 2003; 30:687-696.
24. Matthes E, Lehmann C, Scholz D, Rosenthal HA, Langen P. Phosphorylation, anti-HIV activity and cytotoxicity of 30-fluorothymidine. Biochem Biophys Res Commun 1988; 153:825-831.
25. Turcotte E, Wiens LW, Grierson JR, Peterson LM, Wener MH, Vesselle H. Toxicology evaluation of radiotracer doses of 30-deoxy-30- [18F]fluorothymidine (18)F-FLT for human PET imaging: laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses. BMC Nucl Med 2007; 7:3.
26. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 1991; 266:9032-9038.
27. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 30-deoxy-30-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005; 46:274-282.
28. Auberger J, Kendler D, Virgolini I, Clausen J, Schwaighofer H, Gastl G, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography as a novel noninvasive diagnostic tool for gastrointestinal graft-versus-host disease. Transplantation 2007; 84:440-441.
29. Stelljes M, Hermann S, Albring J, Kohler G, Loffler M, Franzius C, et al. Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. Blood 2008; 111:2909-2918.